Parkinson's disease: NOT your brain; study reveals your ears might hold clues to early signs of the disease

Time of India

a day ago

Parkinson's disease is a progressive neurological disorder that primarily affects movement. It is characterized by the degeneration of nerve cells in the brain, specifically those producing dopamine, a neurotransmitter crucial for coordinating movement.
This leads to a range of symptoms, including tremors, stiffness, and slowness of movement. While there is no cure, treatments and therapies can help manage symptoms and improve quality of life.
Globally, Parkinson's disease (PD) affects millions. A study published in The BMJ in March 2025 projects that 25.2 million people will be living with Parkinson's by 2050.
But what if we can detect Parkinson's disease with an easy hack?
No scans, no invasive tests – imagine being able to early diagnose Parkinson's with a gentle swab of your ear.
Recent research reveals that earwax – or cerumen – may carry subtle chemical signals pointing to Parkinson's disease (PD) long before traditional symptoms appear. By analyzing volatile organic compounds (VOCs) in earwax and feeding that data into artificial‑intelligence systems, scientists have achieved detection accuracy as high as 94%.
This promising approach could offer an easy, non‑invasive, and cost‑effective screening method.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
5 Books Warren Buffett Wants You to Read In 2025
Blinkist: Warren Buffett's Reading List
Undo
Read on to know more.
What does the study say?
The new research, published in
Analytical Chemistry
, has found that volatile organic compounds (VOCs) in earwax could carry chemical signals of the neurological disease.
The work builds on earlier findings suggesting that Parkinson's subtly alters body odor, through changes in sebum, the oily substance that naturally moisturizes our hair and skin.
The problem with trying to analyze sebum on the skin is that its exposure to air and the external environment makes it less reliable for clinical testing.
Scientists led by a team from Zhejiang University wanted to take a look at earwax, which is better protected.
The researchers took ear canal swabs from 209 study participants, 108 of whom had been given a Parkinson's disease diagnosis. By charting differences in earwax composition between people with and without Parkinson's, four VOCs stood out: ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane.
As the researchers mentioned in their published paper, "Early diagnosis and intervention are crucial for Parkinson's disease treatment," adding, "This study proposes a diagnostic model… that analyzes VOCs from ear canal secretions."
According to the scientists, those VOCs can be altered by inflammation, cell stress, and neurodegeneration in the brain. With the right tests, the team hypothesized that subtle signals for Parkinson's could show up in the ears.
These could potentially be used to identify Parkinson's in the future, acting as a foundation around which tests can be developed. First, though, this same analysis needs to be run on larger groups of people over longer periods of time.
Earwax: An unexpected diagnostic window
Earwax, medically known as cerumen, is more than just debris – it contains sebum, an oily secretion from skin glands, along with waxy fatty acids and dead skin cells. Sebum's chemical composition reflects our skin's metabolic activity.
Earlier studies found that people with Parkinson's often emit a distinctive musky odor, traced back to sebum on their skin, caused by inflammation, oxidative stress, and neurodegeneration.
Yet, skin-mounted sebum exposed to pollution and humidity can muddy chemical signals. Enter the ear canal – a more protected environment. Wax from the ear canal remains sheltered, making it a more stable source for detecting sebum-based chemical markers.
The findings: Four key VOCs
The team, led by Hao Dong and Danhua Zhu at Zhejiang University, collected earwax samples from 209 participants –108 diagnosed with Parkinson's and 101 healthy controls. Using advanced separation techniques (gas chromatography–mass spectrometry and GC with surface acoustic wave sensors), they analyzed the chemical makeup of the samples.
Out of hundreds of detected VOCs, four stood out – chemicals whose levels consistently differed in Parkinson's patients:
Ethylbenzene
4‑Ethyltoluene
Pentanal
2‑Pentadecyl‑1,3‑dioxolane
Statistical analysis showed these chemicals were significantly altered in Parkinson's patients.
These differences likely stem from underlying processes in Parkinson's: neurodegeneration, systemic inflammation, oxidative stress, and changes in fat metabolism.
Enter AI – with 94% accuracy
Detecting these VOCs is only one part of the equation – interpreting them demands precision. The researchers built an Artificial Intelligence Olfactory (AIO) system using two methods:
A support‑vector machine trained on GC‑MS data.
A convolutional neural network (CNN) trained on GC‑SAW sensor data.
The CNN-AIO achieved 94–94.4% accuracy in differentiating Parkinson's from non-Parkinson's samples, with an impressive receiver‑operating‑characteristic (ROC) area under the curve (AUC) of ~0.98.
This highlights the system's potential as a reliable early­-screening tool – fast, inexpensive, non‑invasive, and amenable to low-resource medical settings.
As per the researchers, "The AIO-based analytical system underscores its potential for use in bedside medical diagnostic devices, aiding in earlier and more effective treatment for Parkinson's disease patients."
The findings could also help the ongoing study to understand how Parkinson's gets started and how it might be stopped.
Identified VOC changes could possibly be used as a chemical fingerprint, identifying other changes happening because of – or perhaps leading to – the disease.
Why early detection matters:
Currently, Parkinson's is diagnosed based on motor symptoms – tremors, muscle rigidity, slowed movement – when significant neurological damage has already occurred. Conventional diagnostic methods, like brain imaging or dopamine transporter scans, are expensive, time-consuming, and not always precise
Earlier detection through earwax offers three big benefits:
Preventive timing:
Intervene sooner to potentially slow disease progression and preserve quality of life.
Accessibility:
Ear swabs require minimal training and equipment, less costly than imaging.
Consistency:
Earwax sebum isn't easily contaminated, unlike skin sebum.
An affordable, objective test could change the landscape for millions of people worldwide.
What's ahead:
The next steps?
Wider trials across multiple centers and demographics to confirm whether this test is robust in varied populations and stages of Parkinson's, develop bedside protocols using rapid GC-SAW sensors and AI for real-time screening, and explore biological pathways linking VOC changes to cellular processes, which could illuminate PD's origins and potential therapeutic targets.
Researchers Dr. Hao Dong and colleagues emphasize the need for multi-center trials, involving diverse ethnicities and disease stages, before real-world use. As per Dr. Dong, from the Nanjing University of Aeronautics and Astronautics, "The next step is to conduct further research at different stages of the disease, in multiple research centers and among multiple ethnic groups, in order to determine whether this method has greater practical application value.
"
Speech may be clue to early mental decline